basic
research
field
molecular
biolog
led
discoveri
mechan
rna
interfer
rnai
caenorhabd
elegan
rnai
wide
appreci
import
gene
control
mechan
mammal
sever
rnaibas
genesilenc
applic
alreadi
use
clinic
trial
review
discuss
rnai
approach
inhibit
pathogen
human
immunodefici
viru
type
establish
chronic
infect
would
like
requir
durabl
gene
therapi
approach
virus
particularli
difficult
target
rnai
attack
mutat
frequent
allow
viral
escap
mutat
rnai
target
sequenc
combinatori
rnai
strategi
requir
prevent
viral
escap
gene
suppress
effect
rna
interfer
rnai
first
notic
year
ago
plant
transgenesi
studi
describ
mechanist
term
fire
mello
caenorhabd
elegan
recent
studi
underscor
import
rnai
mechan
regul
gene
express
mammalian
cell
role
rnai
mammal
human
process
small
noncod
microrna
mirna
regul
cellular
gene
express
control
cell
differenti
develop
rnai
pathway
also
induc
artifici
substrat
either
transient
transfect
small
interf
rna
sirna
stabli
intracellular
express
short
hairpin
rna
shrna
process
cellular
rnai
machineri
effect
sirna
perfect
basepair
complementar
sirna
target
sequenc
messeng
rna
mrna
result
cleavag
transcript
rnainduc
silenc
complex
risc
sinc
discoveri
rnai
wide
use
gene
knockdown
studi
sever
review
recent
written
mechanist
detail
rnai
action
rnai
propos
novel
therapeut
strategi
specif
inhibit
human
pathogen
virus
acut
viru
infect
influenza
viru
respiratori
syncyti
viru
rsv
therapi
particularli
attract
local
deliveri
sirna
drug
lung
feasibl
anoth
major
advantag
target
acut
viru
infect
singl
sirna
administr
may
suffici
reduc
viral
load
therebi
dampen
avoid
induct
diseas
symptom
viru
subsequ
control
eventu
clear
immun
system
mice
treat
sirna
influenza
viru
rsv
sever
acut
respiratori
syndrom
coronaviru
show
reduc
viru
titer
reduc
virusinduc
mortal
prophylact
sirna
treatment
establish
infect
recent
alnylam
pharmaceut
cambridg
usa
initi
phase
ii
clinic
trial
sirna
treatment
rsv
infect
advers
effect
observ
initi
phase
trial
safeti
toler
antivir
activ
sirna
subsequ
test
adult
experiment
infect
rsv
howev
recent
sirna
result
indic
develop
safe
sirnabas
therapi
might
challeng
gener
expect
alarm
bell
went
new
result
indic
preclin
efficaci
observ
mous
model
macular
degener
probabl
result
nonspecif
side
effect
rather
sequencespecif
rnaimedi
gene
knockdown
recent
studi
confirm
nonspecif
sirna
effect
innat
immun
respons
mistaken
sequencespecif
therapeut
effect
chronic
infect
hepat
b
viru
hepat
c
viru
lifelong
suppli
sirna
probabl
requir
sustain
antivir
effect
scenario
seem
much
difficult
acut
infect
also
persist
virus
tend
escap
impos
rnai
inhibit
recent
studi
howev
advoc
repeat
deliveri
exogen
sirna
antihiv
therapi
viru
replic
control
associ
loss
cell
prevent
mous
model
human
immun
system
obviou
challeng
remain
vivo
deliveri
sirna
relev
cell
type
remain
doubt
whether
one
achiev
maintain
suffici
high
sirna
level
infect
human
durabl
control
viru
replic
incomplet
viru
inhibit
certain
bodi
compart
provid
mean
subsequ
viral
escap
therapi
failur
kumar
colleagu
argu
sirna
therapi
provid
flexibl
chang
sirna
cocktail
order
keep
pace
mutat
viru
inde
frequent
adapt
sirna
drug
regimen
seem
easier
repeatedli
chang
shrnaencod
viral
vector
although
latter
adjust
also
feasibl
howev
therapi
adjust
concept
complex
simpl
chang
sirna
regimen
block
viru
escap
variant
origin
viru
thu
one
ideal
add
new
sirna
exist
sirna
cocktail
viru
escap
notic
strategi
soon
fail
increas
sirna
load
concomit
increas
toxic
eg
satur
rnai
machineri
argu
key
import
prevent
viral
escap
first
place
achiev
combinatori
rnai
approach
gene
therapi
make
cell
resist
constitut
shrna
express
provid
durabl
approach
sever
review
written
antivir
rnai
approach
focu
detail
gene
therapeut
strategi
chronic
infect
fact
phase
clinic
trial
hivaid
recent
launch
viral
vector
deliv
three
inhibitor
gene
includ
antitatrev
shrna
use
viral
gene
therapi
vector
obvious
carri
risk
includ
induct
unwant
immun
respons
andfor
retrovir
lentivir
vectorsth
unknown
consequ
random
integr
vector
human
genom
addit
concern
remain
toxic
relat
shrna
express
interferon
induct
doublestrand
rna
dsrna
molecul
safeti
import
paramet
first
clinic
studi
virus
segment
viral
rna
genom
equal
suscept
rnaimedi
inhibit
protein
bound
viral
rna
may
block
rnai
action
viral
transcript
may
adopt
obstruct
rna
structur
viral
rna
may
protect
insid
virion
particl
viral
rna
may
resid
subcellular
compart
survey
rnai
machineri
nevertheless
earli
studi
indic
rnai
effect
inhibit
replic
stabli
transduc
tcell
line
express
antivir
sirnashrnamirna
although
theoret
two
form
rna
provid
target
rnaiattack
one
form
seem
protect
incom
rna
genom
present
infecti
virion
particl
first
put
target
deliv
cytoplasm
infect
cell
later
infect
cycl
de
novo
synthes
viral
transcript
form
second
mrna
target
rnai
attack
sever
studi
suggest
incom
rna
genom
target
rnai
studi
present
solid
evid
possibl
measur
complet
protect
incom
rna
genom
reason
rnai
machinerythat
risc
complexi
unabl
access
rna
genom
remain
encapsul
core
particl
coat
rna
nucleocapsid
protein
may
also
shield
viral
genom
rnai
attack
one
could
argu
realli
matter
step
replic
cycl
inhibit
long
block
fairli
complet
sever
theoret
criteria
formul
identifi
optim
target
site
rnai
attack
rna
genom
may
benefici
select
target
sequenc
earli
splice
mrna
encod
earli
protein
tat
rev
nef
earli
block
viral
gene
express
serious
hamper
express
late
structur
protein
virion
assembl
ii
may
good
idea
select
target
present
subgenom
rna
instanc
sequenc
untransl
leader
termin
nef
gene
qualifi
present
splice
rna
form
obvious
also
fulllength
genom
rna
iii
genom
may
target
induc
transcript
gene
silenc
tg
viral
long
termin
repeat
ltr
promot
molecular
mechan
tg
requir
descript
transcript
silenc
remain
attract
way
establish
durabl
silenc
epigenet
promot
dna
modif
tg
could
interest
method
achiev
robust
especi
prolong
gene
silenc
effect
iv
may
advis
select
target
part
stabl
rna
structur
discuss
next
paragraph
v
virus
host
coevolv
million
year
virus
develop
mechan
neutral
rnai
action
viral
protein
rna
molecul
may
frustrat
rnai
attack
act
rnai
suppressor
bind
target
sequenc
although
presenc
viral
rnai
suppressor
protein
may
seem
problemat
promis
result
report
suppressorencod
virus
hepat
c
viru
gene
therapi
set
specif
target
viral
rna
encod
suppressor
function
could
consid
thu
better
understand
natur
virusrnai
interact
import
futur
fine
tune
rnaibas
therapi
vi
last
least
import
consider
target
select
sequenc
variat
natur
isol
analyz
use
avail
sequenc
databas
goal
would
design
therapi
activ
mani
strain
possibl
idea
attack
highli
conserv
viral
sequenc
also
relev
prevent
viral
escap
natur
sequenc
variat
provid
obviou
indic
allow
sequenc
variat
thu
likelihood
viral
escap
within
wellconserv
target
sequenc
mani
possibl
rnairesist
mutat
select
impos
high
cost
term
viral
replic
capac
inde
silent
codon
chang
preferenti
select
target
encod
import
protein
domain
thu
visual
restrict
area
sequenc
space
avail
evolut
domain
despit
theoret
consider
remain
import
screen
set
rnai
inhibitor
candid
select
potent
one
sever
studi
describ
select
rnai
escap
mutant
singl
inhibitor
use
differ
class
escap
mutat
observ
major
escap
mutant
acquir
singl
point
mutat
within
target
sequenc
result
underscor
strict
sequenc
specif
rnai
mechan
hand
also
evid
prolong
rnai
inhibit
select
multipl
point
mutat
indic
singl
mutat
may
provid
complet
resist
ii
mutat
outsid
target
sequenc
result
rna
structur
chang
also
observ
exot
escap
rout
studi
reveal
effici
rnai
attack
larg
determin
avail
access
unpair
end
target
sequenc
iii
partial
complet
delet
target
sequenc
form
anoth
escap
rout
nonessenti
viral
genom
segment
delet
describ
shrna
direct
nonessenti
nef
gene
allow
viru
freedom
select
escap
variant
iv
indirect
viral
escap
rout
recent
propos
upon
target
tar
hairpin
motif
involv
transcript
activ
viral
tat
protein
viral
escap
coincid
multipl
number
bind
site
transcript
factor
viral
ltr
promot
thu
transcript
upregul
seem
overcom
impos
rnai
inhibit
howev
argu
adapt
reflect
gener
improv
viru
replic
specif
escap
rnai
attack
similar
duplic
report
evolut
studi
without
rnai
pressur
clinic
success
highli
activ
antiretrovir
therapi
base
combin
multipl
antiretrovir
drug
similar
strategi
counteract
viral
escap
use
multipl
potent
shrna
inhibitor
larg
screen
identifi
potent
shrna
target
highli
conserv
sequenc
enabl
us
design
combinatori
gene
therapi
first
combin
express
multipl
shrna
result
addit
inhibit
compar
individu
inhibitor
second
importantli
viral
escap
difficult
combin
therapi
acquir
resist
mutat
target
time
number
type
mutat
eg
easi
transit
versu
difficult
transvers
similarli
dictat
evolut
drugresist
variant
altern
one
could
includ
secondgener
shrna
specif
target
popular
viral
escap
mutant
previous
estim
chanc
viral
escap
therapi
singl
versu
multipl
shrna
inhibitor
made
assumpt
escap
mean
delet
option
viru
seem
appropri
essenti
viral
gene
target
point
mutat
allow
occur
singl
point
mutat
theori
make
viru
partial
insensit
rnai
error
rate
revers
transcriptas
chanc
viral
escap
target
singl
infect
studi
field
drug
resist
indic
untreat
hivinfect
individu
viru
popul
size
mean
sever
potenti
escap
variant
alreadi
present
shrna
start
therapi
emerg
drugresist
variant
seem
inevit
singl
shrna
use
multipl
shrna
n
use
simultan
likelihood
select
escap
variant
drop
exponenti
number
inhibitor
n
assum
alreadi
resist
least
one
shrna
chanc
resist
variant
emerg
n
instanc
four
shrna
use
simultan
chanc
escap
chanc
seem
remot
given
averag
viral
load
patient
howev
formal
exclud
multishrnaresist
mutant
evolv
vivo
vitro
cell
cultur
infect
experi
observ
delay
viral
escap
two
shrna
viral
escap
four
shrna
find
may
guid
futur
develop
durabl
multishrnabas
gene
therapi
howev
vivo
situat
like
complex
viru
replic
may
continu
cell
modifi
gene
therapi
although
cell
eventu
remov
immun
system
upon
viru
infect
present
viral
epitop
cell
surfac
partial
resist
viru
variant
appear
unmodifi
cell
reservoir
seem
fairli
easi
merg
resist
mutat
mean
recombin
mani
cellular
factor
support
viru
replic
cycl
also
target
altern
rnai
strategi
seem
attract
genet
barrier
viral
escap
may
significantli
higher
instanc
adapt
anoth
cellular
cofactor
may
imposs
altern
cellular
function
avail
stress
concept
yet
proven
experiment
effect
may
vari
wide
differ
cellular
target
silenc
sever
protein
cofactor
test
receptor
coreceptor
integr
factor
barrier
autointegr
emerin
ledgf
len
epitheliumderiv
growth
factor
transcript
factor
nuclear
factor
nf
kinas
cyclin
furin
involv
envelop
protein
matur
silenc
cellular
cofactor
restrict
proteincod
mrna
cellular
mirna
may
also
play
instrument
role
viral
replic
cycl
recent
demonstr
hepat
c
viru
new
molecular
insight
virusrnai
interact
present
new
therapeut
option
mirna
specif
suppress
pathogen
virus
could
use
design
mirna
mimic
new
class
antivir
altern
cellular
mirna
act
viral
cofactor
virallyencod
mirna
could
block
inactiv
antisens
inhibitor
attack
cellular
function
obvious
without
danger
host
gene
target
need
care
select
knockdown
may
detriment
cell
host
instanc
knockdown
desir
therapeut
set
cellsurfac
receptor
play
essenti
role
immun
system
receptor
obviou
attract
target
peopl
carri
defect
gene
show
delay
diseas
progress
peopl
homozyg
healthi
larg
protect
infect
even
partial
silenc
expect
provid
therapeut
benefit
hivinfect
patient
proof
principl
obtain
nonhuman
primat
receiv
blood
stem
cell
treat
siv
lentivir
vector
express
shrna
express
reduc
cell
primat
less
suscept
siv
infect
compar
appropri
control
cell
primat
exhibit
normal
hematopoiet
reconstitut
import
indic
treatment
safe
potenti
gene
therapi
support
intrigu
cure
hivinfect
patient
leukemia
addit
aid
special
bone
marrow
transplant
condit
warrant
high
risk
blood
stem
cell
transplant
match
donor
identifi
mutat
standard
regimen
drug
radiat
administ
prior
transplant
kill
patient
bone
marrow
immun
cell
antiretrovir
treatment
stop
transfus
surprisingli
standard
test
detect
blood
day
post
transfus
result
form
indirect
proof
principl
gene
therapi
approach
one
realiz
high
risk
treatment
bone
marrow
transplant
recipi
surviv
unthink
million
hivinfect
individu
gene
therapi
ideal
reach
mani
differ
cell
type
infect
cell
constitut
major
cell
popul
implic
hiv
infect
progress
aid
make
cell
resist
key
aspect
antihiv
gene
therapi
two
strategi
propos
make
cell
resist
first
strategi
isol
peripher
blood
mononuclear
cell
patient
blood
purifi
cell
cell
subsequ
treat
ex
vivo
viral
vector
antihiv
gene
provid
resist
transduc
cell
subsequ
engraft
back
patient
surviv
improv
immun
patient
cell
limit
life
span
repeat
infus
may
necessari
second
complic
hope
also
durabl
therapeut
scenario
focus
hematopoiet
blood
stem
cell
blood
stem
cell
continu
popul
myeloid
lymphoid
cell
lineag
peripheri
engraft
genet
modifi
autolog
blood
stem
cell
result
steadi
product
new
cell
also
monocyt
macrophag
dendrit
cell
target
stem
cell
singl
gene
therapi
treatment
may
suffic
sustain
therapeut
effect
although
remain
mani
unknown
address
pilot
clinic
studi
hivinfect
individu
resist
cell
preferenti
surviv
unprotect
cell
either
kill
directli
viru
remov
immun
system
upon
recognit
viral
epitop
cell
surfac
stem
cell
gene
therapi
may
lead
partial
reconstitut
immun
system
although
current
difficult
specifi
repair
quantit
tempor
term
lentivir
vector
seem
ideal
suit
durabl
gene
transfer
stabli
integr
genom
target
cell
produc
constant
suppli
antivir
rnai
molecul
lentivir
vector
also
effici
transduct
blood
stem
cell
cell
major
target
cell
hivaid
therapi
howev
vector
system
larg
base
sequenc
express
antivir
shrna
lentivir
vector
may
caus
unwant
complic
vector
product
packag
cell
inde
target
gagpol
rev
mrna
packag
system
reduc
transduct
titer
systemat
address
possibl
rout
shrna
interfer
lentivir
vector
product
lentiviru
product
capsid
titer
transduct
titer
reduc
shrna
gagpol
mrna
howev
problem
could
simpli
avoid
human
codonoptim
gagpol
version
recogn
shrna
target
rev
mrna
packag
cell
affect
lentiviru
product
probabl
limit
amount
rev
protein
need
support
nuclear
rna
export
function
rnai
attack
remain
sequenc
vector
genom
seriou
possibl
avoid
select
shrna
target
absent
lentivir
vector
altern
one
could
actual
modifi
target
sequenc
lentivir
vector
without
affect
import
vector
motif
may
fact
surpris
shrnaencod
lentivir
vector
produc
shrnaencod
sequenc
vector
genom
attack
shrna
also
express
packag
cell
turn
vector
rna
genom
protect
selftarget
stabl
hairpin
structur
mask
target
sequenc
recognit
rnai
machineri
specif
problem
may
encount
combinatori
approach
use
lentivir
vector
system
instanc
report
delet
shrna
cassett
promot
element
use
express
lentivir
vector
found
recombin
repeat
sequenc
transduct
process
result
delet
one
multipl
express
cassett
cell
express
singl
inhibitor
may
form
breed
ground
partial
resist
viru
variant
subsequ
recombin
acquir
multishrna
resist
avoid
recombinationmedi
delet
multipl
shrna
express
differ
promot
element
inde
vector
genom
stabil
improv
four
shrna
express
four
differ
promot
altern
new
shrna
design
may
avoid
use
multipl
promot
element
instanc
one
could
stack
multipl
shrna
modul
top
singl
transcript
driven
singl
promot
element
design
antihiv
molecul
socal
extend
shrna
eshrna
approach
requir
care
design
extend
hairpin
molecul
one
could
also
gener
singl
mirnalik
transcript
encod
multipl
antivir
mirnassirna
incorpor
mirna
sequenc
eg
drosha
cleavag
site
within
context
lentivir
rna
vector
genom
may
also
neg
impact
lentivir
vector
product
transduct
studi
need
optim
vector
system
particular
complic
combinatori
rnai
approach
import
issu
relat
safeti
efficaci
need
address
appropri
anim
model
clinic
trial
consid
sever
potenti
side
effect
report
shrna
instanc
vivo
overexpress
shrna
result
death
mice
due
satur
rnai
machineri
observ
fatal
side
effect
primarili
ascrib
satur
lead
interfer
nuclear
export
mirna
precursor
mirna
function
result
demonstr
rather
dramat
manner
shrna
overdos
danger
howev
mice
receiv
moder
rnai
dose
fine
also
indic
shrna
express
induc
interferon
pathway
origin
paradigm
dsrna
molecul
larger
base
pair
induc
pathway
small
dsrna
shown
evok
reaction
interferon
induct
dose
depend
sequenc
motif
implic
final
rnai
could
also
induc
offtarget
effect
sirna
silenc
partial
complementari
transcript
mirnalik
mechan
effect
requir
basepair
complementar
sirna
seed
region
untransl
region
target
gene
sirna
molecul
like
limit
complementar
number
cellular
gene
number
potenti
offtarget
gene
increas
significantli
combinatori
set
system
induc
tissuespecif
shrna
express
may
control
offtarget
effect
avoid
high
express
level
may
induc
unwant
side
effect
use
multishrna
lentivir
vector
low
multipl
infect
obtain
cell
singl
vector
copi
potent
inhibit
achiev
singl
copi
context
inhibit
remain
stabl
least
day
growth
rate
transduc
cell
line
primari
cell
affect
interferon
dsrnadepend
protein
kinas
system
induc
potenti
side
effect
remain
genuin
concern
develop
multipl
shrna
approach
potenti
risk
properli
assess
preclin
evalu
first
vivo
studi
therapi
efficaci
safeti
perform
mous
model
akkina
colleagu
recent
new
human
mous
model
develop
ideal
suit
preclin
assess
human
c
mous
sustain
longterm
multilineag
human
hematopoiesi
capabl
mount
immun
respons
engraft
human
cell
ex
vivo
transduct
lentivir
vector
express
shrna
nef
gene
shrna
express
affect
develop
stem
cell
variou
matur
leukocyt
subset
includ
cell
replic
test
ex
vivo
demonstr
sequencespecif
inhibit
form
import
proof
concept
clinic
develop
antihiv
rnaibas
gene
therapi
result
indic
procedur
safe
singl
shrna
express
vector
next
step
preclin
evalu
challeng
mice
normal
result
viremia
deplet
cell
main
featur
human
infect
antivir
rnai
strategi
seem
effici
nucleic
acidbas
antivir
approach
probabl
tap
exist
cell
mechan
sever
antivir
rnai
applic
current
test
clinic
trial
rang
transient
sirna
therapi
rsv
infect
gene
therapi
hivinfect
individu
still
earli
day
develop
seem
obviou
ampl
room
improv
activ
specif
rnai
induc
mean
deliveri
antivir
therapi
chronic
infect
evolut
rnairesist
viru
variant
remain
seriou
problem
combinatori
rnai
approach
seem
abl
prevent
viral
escap
fine
tune
rnaibas
therapi
warrant
come
year
like
see
increas
rang
clinic
applic
given
immens
interest
rnai
therapeut
develop
treatment
infect
pathogen
virus
probabl
among
first
success
